Shionogi has lifted its full-year profit guidance as expected royalties from its HIV treatment surpass prior expectations.

The Japanese pharmaceutical company raised its full-year operating profit by 5.7% to ¥185 billion ($1.2 billion), beating analyst estimates.

The group’s Dovato

📰

Continue Reading on The Japan Times

This preview shows approximately 15% of the article. Read the full story on the publisher's website to support quality journalism.

Read Full Article →